| Armstrong, David |
COVER DFUs, NCT05372809: Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs |
|
|
| Terminated | 3 | 42 | US | SkinTE, Autologous Heterogeneous Skin Construct, Control, Standard of Care | PolarityTE, Alira Health | Diabetic Foot | 02/24 | 02/24 | | |
NCT04267640: Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers |
|
|
| Recruiting | 2 | 60 | US | AMG0001, HGF plasmid, Collategene, beperminogene perplasmid, Placebo | AnGes USA, Inc. | Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot | 07/22 | 01/23 | | |
NCT03754465: Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers |
|
|
| Active, not recruiting | 2 | 56 | US | ALLO-ASC-DFU, Hydrogel sheet containing Allogenic Mesenchymal Stem Cells, Hydrogel SHEET(Vehicle control), Hydrogel sheet without Allogenic Mesenchymal Stem Cells | Anterogen Co., Ltd. | Diabetic Foot Ulcer | 11/23 | 05/24 | | |
NCT04497805: Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers |
|
|
| Recruiting | 2 | 64 | US | ALLO-ASC-SHEET, Hydrogel sheet containing Allogenic Mesenchymal Stem Cells | Anterogen Co., Ltd. | Diabetic Foot Ulcer | 12/24 | 06/25 | | |
| Recruiting | 2 | 210 | US | Boot | University of Southern California, Baylor College of Medicine | Diabetic Foot Ulcer | 12/25 | 12/25 | | |
| Recruiting | N/A | 30 | Canada | Colonoscopy | McMaster University | Crohn's Disease of Both Small and Large Intestine | 01/25 | 01/25 | | |
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 200 | US | NuShield | Organogenesis | Diabetic Foot Ulcer | 11/21 | 12/21 | | |
BGWM, NCT06403605: Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 100 | US | Mirragen Wound Matrix, Fibracol | ETS Wound Care, LLC, Professional Education and Research Institute | Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot | 12/24 | 12/24 | | |
| Terminated | N/A | 8 | US | Pulsed splenic ultrasound, Active ultrasound, Ultrasound probe (no energy applied) | General Electric Research | Burn Wound, 2nd Degree Burn of the Skin | 12/24 | 12/24 | | |
NCT05797285: Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers |
|
|
| Completed | N/A | 26 | US | human keratin graft, ProgenaMatrix | ProgenaCare Global, LLC, Professional Education and Research Institute | Ulcer Healing, Diabetic Foot Ulcer | 12/23 | 12/23 | | |
NCT04564443: A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot |
|
|
| Active, not recruiting | N/A | 222 | US | Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application, Offloading, Pressure Relief, Fibracol Wound Dressing, Calcium Alginate | Medaxis, LLC, Professional Education and Research Institute | Diabetic Foot Ulcer, Diabetic Foot | 12/24 | 12/24 | | |
NCT06035523: Clinical Study Evaluating Wound Closure With Endoform™ and Symphony™ |
|
|
| Recruiting | N/A | 50 | US | Endoform™ Antibacterial, Endoform™ Natural, Symphony™ | Aroa Biosurgery Limited, Professional Education and Research Institute | Wound Healing, Diabetic Foot, Chronic Foot Ulcer, Foot Ulcer | 06/24 | 06/24 | | |
| Recruiting | N/A | 60 | Canada | low FODMAP diet, Lactose Sachet, Fructose Sachet, Sorbitol Sachet, Inulin Sachet, AIRE-2 Portable breath analyzer | McMaster University | Inflammatory Bowel Diseases | 09/27 | 12/27 | | |
| Recruiting | N/A | 50 | Canada | L-Tryptophan, Freedom SimpleCap Powder | McMaster University | Tryptophan Metabolism Alterations, Celiac Disease | 04/25 | 06/25 | | |
NCT06681428: Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 240 | US | Allograft | Tides Medical, Professional Education and Research Institute | Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers | 11/26 | 11/26 | | |
NCT06035536: Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 120 | US | Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol | Aroa Biosurgery Limited, Professional Education and Research Institute | Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 45 | Canada | Intermittent Fasting Intervention, Mediterranean Diet Intervention, Low FODMAP Diet Intervention | McMaster University | IBD (Inflammatory Bowel Disease), Ulcerative Colitis (UC), Crohn Disease (CD) | 01/26 | 01/27 | | |
NCT06104969: DFC 004 Biomarkers for Active Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 5000 | US | | University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetic Foot Ulcer, Diabetic Foot, Diabetes | 06/28 | 06/28 | | |
| Recruiting | N/A | 1000 | Canada | | University Health Network, Toronto, Canadian Nutrition Society, Baxter Healthcare Corporation, Ontario Medical Supply | Parenteral Nutrition, Home | 12/29 | 12/29 | | |
| Villella, Jeannine A |
PROTA, NCT05271318: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. |
|
|
| Recruiting | 1 | 29 | Europe, US | TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), pembrolizumab, KEYTRUDA®, MK-3475, pegylated liposomal doxorubicin, PLD | TILT Biotherapeutics Ltd., Merck Sharp & Dohme LLC | Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin | 01/25 | 01/27 | | |
| Halaby, Claudia |
NCT05762978: Evaluation of Negative Inspiratory Flow in Children With Acute Asthma |
|
|
| Completed | N/A | 7 | US | In-Check Dial, Inhaler Device | Winthrop University Hospital | Asthma | 04/18 | 04/18 | | |
| Reiss, Allison B |
NCT01180361: Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance |
|
|
| Recruiting | N/A | 160 | US | | NYU Langone Health, Arthritis Foundation | Rheumatoid Arthritis | 12/25 | 12/25 | | |
| Carsons, Steven |
| Active, not recruiting | 3 | 276 | Europe, US, RoW | VAY736, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Sjogren Syndrome | 05/25 | 05/27 | | |
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Ianalumab (VAY736), VAY736, Placebo | Novartis Pharmaceuticals | Sjogrens Syndrome | 08/28 | 07/30 | | |
NCT01180361: Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance |
|
|
| Recruiting | N/A | 160 | US | | NYU Langone Health, Arthritis Foundation | Rheumatoid Arthritis | 12/25 | 12/25 | | |
| Schneider, Jeffrey |
NCT03315910: Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites |
|
|
| Active, not recruiting | 4 | 807 | US | Motivational Interviewing (MI), Nicotine Replacement Therapy (NRT), Nicotine Lozenge, Message Framing, saliva sample | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Smoking Cessation | 10/25 | 10/25 | | |
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity |
|
|
| Recruiting | 3 | 800 | Europe, US, RoW | Retatrutide, LY3437943, Tirzepatide, LY3298176 | Eli Lilly and Company | Obesity | 04/27 | 04/27 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Staszewski, Harry |
| Not yet recruiting | 2 | 50 | US | AlloStim, Bavencio, Avelumab | Mirror Biologics, Inc. | Metastatic Colorectal Cancer | 06/25 | 11/25 | | |
| Weinblatt, Mark E |
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia |
|
|
| Active, not recruiting | 2/3 | 640 | US, Canada, RoW | Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma | 12/20 | 12/20 | | |
NCT00082745: Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors |
|
|
| Recruiting | N/A | 3885 | Europe, Canada, US, RoW | Laboratory Biomarker Analysis, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Childhood Malignant Neoplasm | 12/04 | | | |
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma |
|
|
| Recruiting | N/A | 10000 | Europe, Canada, US, RoW | Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma | 01/00 | | | |
| Recruiting | N/A | 8000 | Europe, Canada, US, RoW | Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor | 01/00 | | | |
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies |
|
|
| Recruiting | N/A | 5000 | US | Assessment of Therapy Complications, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor | 01/00 | | | |
| Accacha, Siham |
NCT05180591: Repeat BCG Vaccinations for the Treatment of Pediatric Type 1 Diabetes |
|
|
| Recruiting | 2 | 150 | US | Bacillus Calmette-Guérin, BCG, Saline Injection | Massachusetts General Hospital, NYU Langone Health | Diabetes Mellitus, Type 1, Diabetes Type1, Autoimmune Diabetes | 03/27 | 03/27 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
| Brem, Harold |
NCT05797688: Adipose-derived Stem Cells to Treat Chronic Wounds. |
|
|
| Withdrawn | 1 | | US | The Celution System, Celution, Adipose-derived cell processor | Winthrop University Hospital, Cytori Therapeutics | Wound of Skin | 07/17 | 09/17 | | |
| DiGregorio, Julie |
| Recruiting | 4 | 20000 | US | Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet | Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences | Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases | 12/26 | 12/26 | | |
| Katz, Aaron E |
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer |
|
|
| Active, not recruiting | 2/3 | 190 | US | N-803 and BCG, N-803 | ImmunityBio, Inc. | Bladder Cancer | 04/25 | 10/28 | | |
|
|
|
|
|
|
|
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial) |
|
|
| Active, not recruiting | 2 | 234 | US | Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide | Dana-Farber Cancer Institute, Bayer, Decipher Biosciences | Prostate Cancer | 03/25 | 03/28 | | |
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 596 | US | BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation) | ImmunityBio, Inc. | Non-muscle Invasive Bladder Cancer | 12/28 | 12/38 | | |
| Lane, Brian |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer |
|
|
| Active, not recruiting | N/A | 572 | US | | University of Washington, Patient-Centered Outcomes Research Institute | Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer | 12/24 | 03/25 | | |
NCT03193970: Measuring Surgical Recovery After Radical Cystectomy |
|
|
| Recruiting | N/A | 2000 | US | Post-Operative Recovery Registry | M.D. Anderson Cancer Center | Bladder Cancer | 12/34 | 12/34 | | |
| Schwartz, Richard |
| Completed | 2 | 96 | US, RoW | Varespladib Methyl, LY333013, Placebo, Standard of care (SOC) | Ophirex, Inc., Premier Research Group plc | Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake | 06/23 | 06/23 | | |
| Recruiting | N/A | 1150 | US, RoW | Portico transcatheter aortic valve, Commercially available transcatheter aortic valve | Abbott Medical Devices | Aortic Valve Stenosis | 10/19 | 07/25 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
COMPLETE TAVR, NCT04634240: Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement |
|
|
| Recruiting | N/A | 4000 | Canada, US | Percutaneous Coronary Intervention (PCI) | University of British Columbia | Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis | 04/26 | 04/26 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| Recruiting | N/A | 1000 | Canada, US | | Medstar Health Research Institute | Mitral Valve Disease | 02/27 | 02/27 | | |
| Ye, Shicong |
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures |
|
|
| Completed | 2 | 154 | Europe, US, RoW | CVL-865, Placebo | Cerevel Therapeutics, LLC | Seizures | 05/24 | 05/24 | | |
| Marston, William |
C-TRACT, NCT03250247: Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The Trial) |
|
|
| Recruiting | N/A | 250 | US | Stents | Washington University School of Medicine, Ontario Clinical Oncology Group (OCOG), Massachusetts General Hospital, Saint Luke's Mid America Heart Institute | Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome | 01/26 | 04/26 | | |
NCT04927702: Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU) |
|
|
| Terminated | N/A | 47 | US | Synthetic Hybrid-Scale Fiber Matrix, Restrata, Standard of Care, Living Cellular Skin Substitute, Apligraf | Acera Surgical, Inc. | Diabetic Foot Ulcer, Venous Leg Ulcer | 07/24 | 08/24 | | |
NCT05489588: The GORE® VIAFORT Vascular Stent Iliofemoral Study |
|
|
| Active, not recruiting | N/A | 165 | US | GORE® VIAFORT Vascular Stent | W.L.Gore & Associates | Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease | 04/25 | 04/29 | | |
| Ferrara, Louisa |
| Completed | N/A | 22 | US | Standard room temperature (RTS) feeding of milk/formula, Cold temperature (CS, at 4-9°C) of milk/formula | NYU Langone Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Dysphagia of Newborn | 03/24 | 03/24 | | |
| Marotta-Kollarus, Maria |
CLIMB, NCT03492151: Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions |
|
|
| Recruiting | N/A | 500 | US | | Ohio State University Comprehensive Cancer Center, American College of Gastroenterology, The National Pancreas Foundation | Pancreatic Cyst | 12/24 | 12/25 | | |
| Gorenstein, Scott |
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 200 | US | NuShield | Organogenesis | Diabetic Foot Ulcer | 11/21 | 12/21 | | |
NCT04619719: Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia |
|
|
| Terminated | N/A | 27 | US | Hyperbaric Oxygen Therapy (HBOT) | Legacy Health System | Covid19 | 01/22 | 02/23 | | |
| Completed | N/A | 17 | US | Promogran Prisma, Standard of care (SOC) dressings | NYU Langone Health | Skin Graft Disorder, Donor Site Complication | 11/21 | 11/21 | | |
NCT05496296: Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries |
|
|
| Recruiting | N/A | 300 | US | Altrazeal® Transforming Powder Dressing, Standard of Care wound dressings (such as foam, hydrocolloid, collagen, etc) | ULURU Inc., United States Department of Defense | Pressure Ulcers Stage II, Pressure Ulcers Stage III, Pressure Ulcer, Stage IV | 12/23 | 12/23 | | |
| Hanna, Nazeeh |
NCT02935946: Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure |
|
|
| Completed | N/A | 4043 | US | Cold Liquid Barium | NYU Langone Health, Adelphi University | Deglutition Disorders, Respiratory Aspiration | 03/24 | 03/24 | | |
| Completed | N/A | 22 | US | Standard room temperature (RTS) feeding of milk/formula, Cold temperature (CS, at 4-9°C) of milk/formula | NYU Langone Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Dysphagia of Newborn | 03/24 | 03/24 | | |
| Gaztanaga, Juan |
| Recruiting | N/A | 450 | Canada, US | OCT, CMR | NYU Langone Health | Myocardial Infarction | 06/26 | 06/26 | | |
| Corcoran, Anthony |
NCT03193970: Measuring Surgical Recovery After Radical Cystectomy |
|
|
| Recruiting | N/A | 2000 | US | Post-Operative Recovery Registry | M.D. Anderson Cancer Center | Bladder Cancer | 12/34 | 12/34 | | |
| Drewes, Wendy |
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation |
|
|
| Recruiting | 3 | 5350 | US | AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI) | Atrial Fibrillation | 07/29 | 07/29 | | |
| Recruiting | N/A | 450 | Canada, US | OCT, CMR | NYU Langone Health | Myocardial Infarction | 06/26 | 06/26 | | |
| Completed | N/A | 973 | US | Non-Interventional | Medtronic Cardiac Rhythm and Heart Failure | Atrial Fibrillation | 01/24 | 01/24 | | |
| Marzo, Kevin |
| Recruiting | N/A | 450 | Canada, US | OCT, CMR | NYU Langone Health | Myocardial Infarction | 06/26 | 06/26 | | |
| Desouza, Shilpa |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/25 | 12/25 | | |
| Ilowite, Jonathan |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
| Koenig, Jan A |
NCT06203756: Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty |
|
|
| Active, not recruiting | N/A | 642 | US | Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC, BalanceBot, Apex Knee System, Active Spacer, Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS, Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision | Corin | Arthroplasties, Knee Replacement | 03/21 | 04/31 | | |
| Ghafary, Maryum |
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer |
|
|
| Active, not recruiting | 2/3 | 190 | US | N-803 and BCG, N-803 | ImmunityBio, Inc. | Bladder Cancer | 04/25 | 10/28 | | |
|
|
|
|
|
|
|
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 596 | US | BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation) | ImmunityBio, Inc. | Non-muscle Invasive Bladder Cancer | 12/28 | 12/38 | | |
| Pinales, Eymi |
| Active, not recruiting | 3 | 276 | Europe, US, RoW | VAY736, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Sjogren Syndrome | 05/25 | 05/27 | | |
| Ritchie, Angela |
| Active, not recruiting | 3 | 276 | Europe, US, RoW | VAY736, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Sjogren Syndrome | 05/25 | 05/27 | | |
| Shevchuk, Iryna |
| Recruiting | 3 | 406 | Europe, Canada, Japan, US, RoW | Ianalumab, VAY736, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Systemic Lupus Erythematosus | 01/27 | 04/29 | | |
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Ianalumab (VAY736), VAY736, Placebo | Novartis Pharmaceuticals | Sjogrens Syndrome | 08/28 | 07/30 | | |
